<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445911</url>
  </required_header>
  <id_info>
    <org_study_id>KQ-791-02</org_study_id>
    <nct_id>NCT02445911</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of KQ-791 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaneq Bioscience Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaneq Bioscience Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Fasting Blood Glucose</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with one or more Treatment-Emergent Adverse Events</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Insulin Sensitivity Index (ISI)</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beta Cell Function</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disposition Index</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Hepatic Insulin Resistance Index</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 7-point average blood glucose</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in postprandial glucose</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to 24-hours Post-Dose (AUC0-24)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum measured plasma concentration (Tmax)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUCtau)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration at steady-state (Cmax_ss)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum measured plasma concentration at steady-state (Tmax_ss)</measure>
    <time_frame>Pre-dose up to 24 hour post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose on Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>KQ-791 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KQ-791 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose on day 1, followed by a daily dose for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KQ-791 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending doses matching KQ-791 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KQ-791</intervention_name>
    <description>Capsules administered orally</description>
    <arm_group_label>KQ-791 Dose 1</arm_group_label>
    <arm_group_label>KQ-791 Dose 2</arm_group_label>
    <arm_group_label>KQ-791 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  Be an adult between the ages of 18 (19 for Lincoln site) and 70 years

          -  Female participants must be of non-childbearing potential, and must be either 1)
             postmenopausal with amenorrhea for at least 1 year prior to the first dose and
             Follicle Stimulating Hormone (FSH) serum levels consistent with postmenopausal status,
             or 2) have undergone one of the following sterilization procedures at least 6 months
             prior to the first dose:

               -  hysteroscopic sterilization

               -  bilateral tubal ligation or bilateral salpingectomy

               -  hysterectomy

               -  bilateral oophorectomy

          -  Non-vasectomized males must agree to use a condom with spermicide or abstain from
             sexual intercourse during the study until 100 days beyond the last dose of study drug.
             (No restrictions are required for a vasectomized male provided his vasectomy has been
             performed 4 months or more prior to first dosing. A male who has been vasectomized
             less than 4 months prior to first dosing must follow the same restrictions as a
             non-vasectomized male)

          -  Males must agree to not donate sperm during the study and for 100 days following the
             last dose

          -  Have an HbA1c value between 7.0-10.0%

          -  Be on a stable treatment regimen of metformin, with or without diet/exercise, for at
             least 8 weeks

          -  Weigh 60 kilograms (kg) or more at screening and have a body mass index (BMI) greater
             than or equal to (≥) 25.0 and less than or equal to (≤) 40.0 kilograms/meters squared
             (kg/m2)

          -  Have laboratory test results within the normal range for T2DM population, or with
             abnormalities deemed clinically insignificant. Urine protein levels must be within
             normal limits

          -  Absence of active diabetic retinopathy (Stage 2 or greater by the International
             Clinical Disease Severity Scale for Diabetic Retinopathy)

          -  Are willing to comply with specific dietary restrictions (that is, [i] able to fast
             overnight for at least 8-12 hours on several days and [ii] able to consume the
             standard meals provided during specified confinement days)

          -  Have given written consent to allow collection of samples for Peripheral Blood
             Mononuclear Cells (PBMC) analysis and for possible biomarkers/safety analysis

          -  Have given written informed consent approved by the institutional review board (IRB)
             governing the site

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product or
             off-label use of a drug or device, or are concurrently enrolled in any other type of
             medical research judged not to be scientifically or medically compatible with this
             study

          -  Participated (defined as the last dose of study drug) within 30 days prior to dosing
             in a clinical trial involving an investigational product or non-approved use of a drug
             with a short half-life or within 5 half-lives of an investigational product with a
             half-life longer than 6 days

          -  - Have a (QTcF) greater than (&gt;) 450 milliseconds (msec), or clinical significant
             hypokalemia, a family history of long QT syndrome or any abnormality in the 12-lead
             Electrocardiogram (ECG)

          -  Abnormal blood pressure (sitting) defined as diastolic blood pressure &gt; 95 or less
             than (&lt;) 50 millimeter of mercury (mmHg) and/or systolic blood pressure &gt; 160 or &lt; 90
             mmHg

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs

          -  Show evidence of regular use of known drugs of abuse and/or positive findings on
             urinary drug screening

          -  Evidence of human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C
             and/or positive results at screening for the respective antibodies for HIV, hepatitis
             B surface antigen (HBsAg), or hepatitis C antibodies (HCV)

          -  Have anemia that would interfere with the trial or have donated ≥500 mL of blood
             within 56 days before the first dose or have donated plasma within 7 days before the
             first dose or provided any blood donation within last 30 days

          -  Have an average weekly alcohol intake that exceeds 14 units per week (males) and 7
             units per week (females) [1 unit = 12 ounces (oz) or 360 mL of beer, 5 oz or 150 mL of
             wine, or 1.5 oz or 45 mL of distilled spirits] or are unwilling to stop alcohol
             consumption 48 hours prior to the first dosing and throughout the study

          -  Consume more than 10 cigarettes per day or the equivalent or are unable or unwilling
             to adhere to restricted smoking policies

          -  Have had &gt;1 episode of documented severe hypoglycemia within last 6 months or are
             currently diagnosed as having hypoglycemia unawareness

          -  Have any of the following clinical laboratory test results:

               -  estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (impaired renal
                  function)

               -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels &gt; 1.5
                  times (x) the upper limit of normal (ULN)

               -  triglycerides (TG) &gt; 500 milligrams/deciliter (mg/dL)

          -  Have used insulin or other glycemic control medications, except metformin, for
             diabetic control within 3 months

          -  Intend to use non-steroidal anti-inflammatory drugs (except aspirin) and drugs known
             to prolong QT interval, herbal products, or vitamin supplements that change glucose
             levels. The following medications are allowed for participants:

               -  drugs for treatment of hypertension or lipid disorders (except bile acid resins,
                  niacin or fish oils), platelet inhibitors, and on stable dose for 12 weeks prior
                  to first dose

               -  thyroid replacement therapy, proton pump inhibitors, antidepressants,
                  antihistamines, regularly taken over-the-counter (OTC) and anti-emetics that do
                  not cause a corrected QT interval (QTc) prolongation, provided such drugs are not
                  specifically excluded

               -  hormonal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: daniel.bouthillier@Kaneq.ca</last_name>
    <role>Study Director</role>
    <affiliation>Kaneq Bioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 28, 2017</submitted>
    <returned>April 11, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

